SGO 2019: Despite Missed Endpoint, JAVELIN Trial PD-L1 Subgroup Analysis Redeems

Leggi l'articolo originale


Avelumab alone or with pegylated liposomal doxorubicin did not improve survival in this phase III trial, but a subgroup analysis showed promising findings.

Lascia un commento